Navigation Links
New sickle cell anemia therapy advances to Phase II clinical trials
Date:6/12/2013

e print edition of the journal Blood on April 25th, 2013.

David G. Nathan, M.D., president emeritus of the Dana-Farber Cancer Institute, who is the trial's co-lead investigator with Dr. Linden and Joshua Field, M.D., of the BloodCenter of Wisconsin, says he is excited by the prospect of reducing some of the worst symptoms of sickle cell disease, particularly periodic disease exacerbations that lead to severe pain or breathing problems, known as vaso-occlusive crises and acute chest syndrome, respectively. Patients typically do not live beyond their late 40s or early 50s, with pulmonary problems being the most common cause of death.

"Pulmonary complications of sickle cell disease can be fatal because blood flow problems restrict the amount of oxygen going to the lungs," says Dr. Nathan, former physician-in-chief at Boston Children's Hospital and one of the world's top sickle-cell experts. "We are hopeful that the drug will reduce pulmonary injury and extend the lives of sickle cell patients."

In sickle cell anemia, the oxygen-carrying red blood cells become stiff, sticky and misshapen or "sickled" in appearance. This leads to poor blood flow that deprives tissues of oxygen and causes symptoms such as severe pain, difficulty breathing and damage to multiple organs. An inherited disorder, sickle cell anemia occurs in individuals who inherit two copies of the sickle cell geneone from each parent. It is most common in persons of African descent, but is also found in Hispanics of Caribbean ancestry, and people of Middle Eastern, Asian, Indian, Latin American, Native American, and Mediterranean heritage.

"I treat patients with sickle cell anemia in my clinic every day," says Dr. Field. "It is a devastating disease and therapies for the two most common complications, pain and acute chest syndrome, are very limited. Lexiscan has the potential to help people with sickle cell anemia by decreasing the severity of these life-th
'/>"/>

Contact: Bonnie Ward
contact@liai.org
619-303-3160
La Jolla Institute for Allergy and Immunology
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial?
2. Potential gene therapy approach to sickle cell disease highlighted at ASH
3. Nature study reveals loss of essential blood cell gene leads to anemia
4. Why a hereditary anemia is caused by genetic mutation in mechanically sensitive ion channel
5. Cleveland Clinic research shows anemia drug does not improve health of anemic heart failure patients
6. Discovery may help prevent chemotherapy-induced anemia
7. Scientists identify potential drug target for treatment-resistant anemias
8. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
9. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
10. New insight into mechanisms behind autoimmune diseases suggests a potential therapy
11. The Japanese traditional therapy, honokiol, blocks key protein in inflammatory brain damage
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/14/2014)... international team of researchers, led by the Chinese Academy ... Nature Genetics a brief genomic history of ... the tomato plant. , The C.M. Rick Tomato Genetics ... in this study by providing seed of both cultivated ... which builds on the first tomato genome sequence completed ...
(Date:10/14/2014)... past decades, we have seen numerous tragic examples where ... infants for social contact and stimulation has led to ... , Infancy and childhood are critical life periods that ... research suggests that enriched environments, full of interesting stimuli ... contrast, deprivation and stress may compromise cortical development and ...
(Date:10/14/2014)... N.Y. — An oral biologic medication has successfully treated ... of an animal study authored by an MD/PhD student ... Biomedical Sciences. , The study is featured on ... Research ; it was published online ahead of print ... as "striking." , Inflammatory cells in the colon, or ...
Breaking Biology News(10 mins):Institutional rearing may increase risk attention-deficit disorder 2Oral drug reduces formation of precancerous polyps in the colon, UB researchers find 2Oral drug reduces formation of precancerous polyps in the colon, UB researchers find 3
... humans from Chimpanzees? Is it the genetics of ... To Professor Wallace Arthur it is all of these ... Developmental Approach sits between the traditional population approach ... a complete view on the evolutionary development of our ...
... of Oklahoma President David L. Boren announced today that ... using the University,s research expertise to benefit Oklahoma and ... The institute will be led by a national expert, ... funded by a $2 million gift from Corix, a ...
... of the journal Nanomedicine could provide the ... one that would use an outside-the-body filtration device to ... that often create secondary tumors. Researchers at the ... and are working with a medical device firm to ...
Cached Biology News:OU establishes a new water and sustainability institute 2OU establishes a new water and sustainability institute 3Study suggests new treatment option to reduce metastasis in ovarian cancer 2Study suggests new treatment option to reduce metastasis in ovarian cancer 3Study suggests new treatment option to reduce metastasis in ovarian cancer 4
(Date:10/20/2014)... - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") today announced ... $5.8 million and provides a good start to Q4.  The orders ... and one in the Middle East ... levels," said Peter Bruijns , President & CEO. "Total bidding ... than they have been for any complete year since the company ...
(Date:10/20/2014)... , Oct. 20, 2014 PureTech , ... tackling big healthcare problems, announced today the closing ... with participation from Invesco Perpetual, a $120 Billion ... to drive PureTech,s existing pipeline forward and to ... has the scientific creativity to really go for ...
(Date:10/20/2014)... 20, 2014 Local veterinary surgeon, Dr. ... investigational study of donor stem cells for dogs with ... therapy and has performed clinical stem cell therapy for ... to determine if a single injection of donor stem ... help reduce pain and inflammation in the treated joints. ...
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which enables ... genome in real time, today announced the launch of its ... Exchange , at the American Society of Human Genetics (ASHG) ... learn more, sign up and apply for free beta access, ... features and benefits can be viewed here . ...
Breaking Biology Technology:PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6Cascade Veterinary Referral Center Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3
... Experience To Antimicrobial Leader.SHREVEPORT, La., March 23 ... in the poultry industry, has joined SteriFx Inc. ... to SteriFx, a leader in developing non-toxic antimicrobial ... defense and other industries. "We,re honored and thrilled ...
... DIEGO, March 23 Nereus Pharmaceuticals, Inc., a ... today announced that it is conducting a randomized ... agent (VDA) NPI-2358 in combination with standard chemotherapy ... (NSCLC). This study follows on positive outcomes ...
... Based on its recent analysis of ... Sullivan presents Nanopoint, Inc. with the 2009 ... Product Innovation of the Year. The company,s ... sophisticated, on-microscope incubator and integrated fluidics system ...
Cached Biology Technology:Dan Blackshear Joins SteriFx Inc. 2Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 2Nereus Pharmaceuticals Initiates ADVANCE, a Randomized Phase 2 Clinical Trial of NPI-2358 in Non-Small Cell Lung Cancer 3Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 2Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 3Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 4Frost & Sullivan Recognizes Nanopoint for its Pioneering Cell Imaging Solution, the cellTRAY(R) Imaging System CT-2000 5
Blasticidin resistance gene (bsr), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
... for stabilizing 400g of purified RNA samples., ... the stabilization of aqueous RNA samples that ... as guanidine, phenol/chloroform, silica, oligo dT etc ... contain all the necessary components for the ...
Hygromycin resistance gene (hph), provided in a pORF plasmid. pORF is an expression plasmid selectable with Ampicillin....
These are replacement caps for No. CLS6980 5mm PYREX NMR tubes. Proper method to remove caps is to slice them from the tube. Caps come in eight assorted/mixed colors. Packed in bags of 100....
Biology Products: